不同药物腔内灌注治疗恶性胸腹腔积液的疗效对比研究  

Comparative study on the efficacy of inject different drugs into the cavity in the treatment of malignant hydrothorax and ascites

作　　者：冷月婷 陈红[1] 王旭东 周楷东 LENG Yueting;CHEN Hong;WANG Xudong;ZHOU Kaidong(Department of Oncology,Anshun People's Hospital,Anshun,Guizhou,561000,China)

机构地区：[1]安顺市人民医院肿瘤科,贵州561000

出　　处：《江西医药》2021年第9期1349-1352,共4页Jiangxi Medical Journal

基　　金：安顺市科技计划基金资助项目,编号:安市科社[2019]04号。

摘　　要：目的对比不同药物治疗恶性胸腹腔积液的有效性和安全性。方法回顾性分析我院2017年12月-2020年12月收治的恶性胸腹腔积液患者94例,根据腔内灌注药物不同分为恩度组26例、洛铂组32例和艾迪组36例,治疗后比较三组患者的近期疗效、生活质量改善率和不良反应发生情况。结果恩度组总有效率为73.08%,洛铂组总有效率为68.75%,均高于艾迪组(P<0.05);恩度组和洛铂组生活质量改善率显著高于艾迪组,差异有统计学意义(P<0.05);洛铂组的不良反应发生率高于其他两组(P<0.05)。常见的不良反应为乏力、恶性呕吐、胸痛或腹痛、骨髓抑制,均为Ⅰ~Ⅱ级,无Ⅲ~Ⅳ级不良反应发生。结论腔内灌注恩度和洛铂治疗恶性胸腹腔积液近期有效率高,可改善患者生活质量,但洛铂的不良反应发生率高,应注意预防。Objective To compare the effectiveness and safety of different drugs in the treatment of malignant hydrothorax and ascites.Methods A retrospective analysis of 94 patients with malignant hydrothorax and ascites admitted to our hospital from December 2017 to December 2020.According to the different intracavitary infusion drugs,they were divided into 26 cases in Endostar group,32 cases in Lobaplatin group and 36 cases in Aidi group.After treatment,compare the short-term efficacy,quality of life improvement rate and adverse reactions of the three groups.Results The total effective rate of Endostar group was 73.08%,Lobaplatin group was 68.75%,both higher than the Aidi group(P<0.05);The quality of life improvement rate of Endostar group and Lobaplatin group was significantly higher than that of Aidi group,the difference was statistically significant(P<0.05);The incidence of adverse reactions in the lobaplatin group was higher than the other two groups(P<0.05).The common adverse reactions were fatigue,malignant vomiting,chest pain or abdominal pain,and bone marrow suppression,all of which were grade Ⅰ to Ⅱ,and no adverse reactions of grade Ⅲ to Ⅳ occurred.Conclusion Intracavitary perfusion of endostar and lobaplatin is effective in the treatment of malignant hydrothorax and ascites and can improve the quality of life of patients.However,Lobaplatin has a high incidence of adverse reactions,and attention should be paid to prevention.

关 键 词：重组人血管内皮抑制素/恩度 洛铂 艾迪 恶性胸腔积液 恶性腹腔积液 疗效 

分 类 号：R730.6[医药卫生—肿瘤]